Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside Citadel, Ken Griffins hedge fund, materially increased its stake in AbbVie; heres why you may want to follow that lead.…
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.…
AbbVies Atogepant Meets Goal in Late-Stage Menstrual Migraine Study ABBVs atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.…
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVies diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.…
AbbVies Immunology Franchise: From Skyrizi & Rinvoq to Whats Next ABBVs Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.…
ROUNDUP: Botox und Co. - Minimalinvasive Eingriffe immer gefragter BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…